Pharming (PHAR) Group announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restructuring is aligned with previously announced plan to reduce general and administrative expenses to optimize capital allocation across the organization. The restructuring includes a redesign of Pharming’s organizational structure and a 20% net reduction in non-commercial and non-medical headcount, primarily at the Netherlands headquarters. The company said, “We remain on track to reduce total G&A expenses by 15% or $10M annually and anticipate one-time restructuring costs of approximately $7M to be recorded in the fourth quarter of 2025 in connection with the headcount reduction.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAR:
- Pharming Group’s Leniolisib Gains FDA Approval for Pediatric Use, Expanding Market Potential
- Pharming Group’s Leniolisib Receives FDA Priority Review for Pediatric APDS Treatment
- Pharming Group Joins Euronext AMX® Index Reflecting Growth Momentum
- Pharming Group Appoints Kenneth Lynard as CFO Amid Strong Financial Performance
- = Pharming Group NV ADS trading resumes
